|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CGA |
Gene summary for CGA |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CGA | Gene ID | 1081 |
| Gene name | glycoprotein hormones, alpha polypeptide | |
| Gene Alias | CG-ALPHA | |
| Cytomap | 6q14.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P01215 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1081 | CGA | GSM4909307 | Human | Breast | IDC | 1.11e-28 | 6.67e-01 | 0.1569 |
| 1081 | CGA | GSM4909308 | Human | Breast | IDC | 1.19e-15 | 3.73e-01 | 0.158 |
| 1081 | CGA | GSM4909319 | Human | Breast | IDC | 1.48e-02 | 2.39e-01 | 0.1563 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:20007794 | Thyroid | PTC | regulation of double-strand break repair | 42/5968 | 85/18723 | 5.59e-04 | 3.56e-03 | 42 |
| GO:003210316 | Thyroid | PTC | positive regulation of response to external stimulus | 167/5968 | 427/18723 | 8.31e-04 | 5.13e-03 | 167 |
| GO:00022186 | Thyroid | PTC | activation of innate immune response | 28/5968 | 52/18723 | 8.33e-04 | 5.13e-03 | 28 |
| GO:00324796 | Thyroid | PTC | regulation of type I interferon production | 45/5968 | 95/18723 | 1.13e-03 | 6.63e-03 | 45 |
| GO:00326066 | Thyroid | PTC | type I interferon production | 45/5968 | 95/18723 | 1.13e-03 | 6.63e-03 | 45 |
| GO:00063026 | Thyroid | PTC | double-strand break repair | 103/5968 | 251/18723 | 1.30e-03 | 7.40e-03 | 103 |
| GO:00516077 | Thyroid | PTC | defense response to virus | 108/5968 | 265/18723 | 1.34e-03 | 7.55e-03 | 108 |
| GO:01405467 | Thyroid | PTC | defense response to symbiont | 108/5968 | 265/18723 | 1.34e-03 | 7.55e-03 | 108 |
| GO:00713602 | Thyroid | PTC | cellular response to exogenous dsRNA | 12/5968 | 18/18723 | 2.55e-03 | 1.31e-02 | 12 |
| GO:00450887 | Thyroid | PTC | regulation of innate immune response | 89/5968 | 218/18723 | 3.16e-03 | 1.55e-02 | 89 |
| GO:00903424 | Thyroid | PTC | regulation of cell aging | 29/5968 | 61/18723 | 7.57e-03 | 3.23e-02 | 29 |
| GO:00510532 | Thyroid | PTC | negative regulation of DNA metabolic process | 53/5968 | 125/18723 | 8.39e-03 | 3.53e-02 | 53 |
| GO:00433312 | Thyroid | PTC | response to dsRNA | 26/5968 | 55/18723 | 1.21e-02 | 4.75e-02 | 26 |
| GO:005105219 | Thyroid | ATC | regulation of DNA metabolic process | 183/6293 | 359/18723 | 5.97e-12 | 2.30e-10 | 183 |
| GO:200102026 | Thyroid | ATC | regulation of response to DNA damage stimulus | 121/6293 | 219/18723 | 3.22e-11 | 1.08e-09 | 121 |
| GO:000756829 | Thyroid | ATC | aging | 166/6293 | 339/18723 | 2.79e-09 | 6.60e-08 | 166 |
| GO:0009615111 | Thyroid | ATC | response to virus | 173/6293 | 367/18723 | 4.23e-08 | 7.71e-07 | 173 |
| GO:000756924 | Thyroid | ATC | cell aging | 72/6293 | 132/18723 | 5.77e-07 | 8.15e-06 | 72 |
| GO:000628211 | Thyroid | ATC | regulation of DNA repair | 68/6293 | 130/18723 | 8.19e-06 | 8.27e-05 | 68 |
| GO:200102114 | Thyroid | ATC | negative regulation of response to DNA damage stimulus | 46/6293 | 81/18723 | 1.51e-05 | 1.41e-04 | 46 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CGA | SNV | Missense_Mutation | c.30N>G | p.Ile10Met | p.I10M | protein_coding | deleterious_low_confidence(0.02) | benign(0.295) | TCGA-A2-A0YM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CGA | SNV | Missense_Mutation | novel | c.232N>A | p.Ala78Thr | p.A78T | protein_coding | tolerated(0.53) | benign(0.121) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CGA | SNV | Missense_Mutation | c.433C>G | p.His145Asp | p.H145D | protein_coding | deleterious(0) | possibly_damaging(0.871) | TCGA-C5-A1BF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | ||
| CGA | SNV | Missense_Mutation | rs145503313 | c.322N>A | p.Val108Ile | p.V108I | protein_coding | tolerated(1) | benign(0.001) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CGA | SNV | Missense_Mutation | novel | c.373N>A | p.Val125Ile | p.V125I | protein_coding | tolerated(0.52) | benign(0.073) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CGA | SNV | Missense_Mutation | c.185N>A | p.Cys62Tyr | p.C62Y | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| CGA | SNV | Missense_Mutation | c.317N>C | p.Lys106Thr | p.K106T | protein_coding | deleterious(0) | possibly_damaging(0.836) | TCGA-AG-A026-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
| CGA | SNV | Missense_Mutation | novel | c.4N>A | p.Asp2Asn | p.D2N | protein_coding | tolerated_low_confidence(0.07) | possibly_damaging(0.856) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CGA | SNV | Missense_Mutation | c.297N>T | p.Lys99Asn | p.K99N | protein_coding | deleterious(0.05) | possibly_damaging(0.51) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CGA | SNV | Missense_Mutation | rs745838602 | c.407N>T | p.Ala136Val | p.A136V | protein_coding | deleterious(0.01) | benign(0.003) | TCGA-D1-A15W-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | VINBLASTINE | VINBLASTINE | 6181870 | |
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | 4-{([(4'-CHLOROPHENYL)AMINO]CARBONYLAMINO)}BENZENESULFONAMIDE | CHEMBL1446150 | ||
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | CIS-DIAMMINEDICHLOROPLATINUM | 6181870 | ||
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | TUMOR NECROSIS FACTOR | 9764349,10788437 | ||
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | IL-18 | 11712764 | ||
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | 9-CIS-RETINOIC ACID | 8070357 | ||
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | TESTOSTERONE | TESTOSTERONE | 1157041 | |
| 1081 | CGA | DRUGGABLE GENOME, HORMONE ACTIVITY | CORTICOSTEROIDS | 3106008 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |